Italian Journal of Pediatrics (Oct 2012)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma

  • Sato Yuya,
  • Kurosawa Hidemitsu,
  • Fukushima Keitaro,
  • Okuya Mayuko,
  • Hagisawa Susumu,
  • Sugita Kenichi,
  • Arisaka Osamu,
  • Inaki Anri,
  • Wakabayashi Hiroshi,
  • Nakamura Ayane,
  • Fukuoka Makoto,
  • Kayano Daiki,
  • Kinuya Seigo

DOI
https://doi.org/10.1186/1824-7288-38-53
Journal volume & issue
Vol. 38, no. 1
p. 53

Abstract

Read online

Abstract Iodine-131-metaiodiobenzylguanidine (131I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. Although 131I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. Based on our findings, we suggest that 131I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible.

Keywords